CGEN
Compugen Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.03
+1.00%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.02
From 52W high−34.52%
Volume202920.00
Market cap$192.30M
P/E (TTM)5.4x
P/S (TTM)2.6x
Div yield—
Key dataNov 4, 2026
Open
$2.02
From 52W high
−34.52%
Volume
202920.00
Market cap
$192.30M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.0x
P/E (TTM)
5.4x
RSI (14)
42.6
MomentumView details →
1D Return
+1.00%
YTD Return
+30.39%
SummaryUpdated Jun 1, 2026
Compugen Ltd. (NASDAQ:CGEN) is an Israeli clinical-stage biotechnology company founded in 1993 and headquartered in Holon, Israel. The company went public in 2000 and has evolved from its origins in computational biology to become a focused immuno-oncology drug developer. Compugen utilizes its proprietary computational discovery platform to identify novel immune checkpoint targets and develops therapeutic antibodies to treat cancer patients. The company has established strategic partnerships with major pharmaceutical companies including AstraZeneca, Bayer, and Gilead Sciences to advance its pipeline of innovative cancer treatments.
Similar companies
Latest newsMore news →
Compugen Ltd. announced it will host a virtual key opinion leader event on October 5, 2026, covering COM701 in ovarian cancer and an update on its Unigen platform.43d agoCompugen reported its financial results for the second quarter of 2026, highlighting a solid financial position with cash runway expected to fund operations into 2029.93d ago